• Asep Medical restructured holdings in ABT Innovations, Sepset Biosciences, cutting indirect stakes to 45% from 50.1%.
• Settlement included intercompany debt resolution, issuance of one nonvoting preferred share in each unit to preserve economics.
• Preferred shares provide quarterly profit-based entitlement, structured similar to a royalty, with priority payout on liquidation events.
• CSE will reclassify Asep Medical as an investment company under exchange policies; name, symbol, CUSIP unchanged.
• Governance rights remain, including board representation, consent rights; Asep Medical plans continued support for development and commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asep Medical Holdings Inc. published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.